DUBLIN--(BUSINESS WIRE)--The "Systemic Lupus Erythematosus - Market Insights, Epidemiology and Market Forecasts to 2027" drug pipelines has been added to ResearchAndMarkets.com's offering.
This report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of SLE in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.
The report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Systemic Lupus Erythematosus (SLE) from 2016 to 2027 segmented by seven major markets. The report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.
According to research, the market of Systemic Lupus Erythematosus in 7MM was found to be more than USD 720 million in 2016.
The total number of prevalent and diagnosed population of Systemic Lupus Erythematosus (SLE) was found to be more than 576,232 and 850,000 in 7MM respectively, in the year 2016.
- GlaxoSmithKline PLC
- Janssen Research & Development
- Merck KgaA
Key Topics Covered:
1. Report Introduction
2. Systemic Lupus Erythematosus (SLE) Market Overview at a Glance
3. Disease Background and Overview: Systemic Lupus Erythematosus (SLE)
4. Epidemiology and Patient Population
5. Epidemiology of Systemic Lupus Erythematosus (SLE)
6. Treatment Practices
7. Unmet Needs
8. Marketed Drugs
9. Emerging Therapies
10. Market Size of Systemic Lupus Erythematosus for 7MM
11. Market Drivers
12. Market Barriers
14. Report Methodology
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/hhswzg/systemic_lupus?w=4